Literature DB >> 17489969

Ordered multiple comparisons with the best and their applications to dose-response studies.

K Strassburger1, F Bretz, H Finner.   

Abstract

This article considers the problem of comparing several treatments (dose levels, interventions, etc.) with the best, where the best treatment is unknown and the treatments are ordered in some sense. Order relations among treatments often occur quite naturally in practice. They may be ordered according to increasing risks, such as tolerability or safety problems with increasing dose levels in a dose-response study, for example. We tackle the problem of constructing a lower confidence bound for the smallest index of all treatments being at most marginally less effective than the (best) treatment having the largest effect. Such a bound ensures at confidence level 1 -alpha that all treatments with lower indices are relevantly less effective than the best competitor. We derive a multiple testing strategy that results in sharp confidence bounds. The proposed lower confidence bound is compared with those derived from other testing strategies. We further derive closed-form expressions for power and sample size calculations. Finally, we investigate several real data sets to illustrate various applications of our methods.

Mesh:

Year:  2007        PMID: 17489969     DOI: 10.1111/j.1541-0420.2007.00813.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  3 in total

1.  Statistical Methods for Selecting Maximum Effective Dose and Evaluating Treatment Effect When Dose - Response is Monotonic.

Authors:  Maiying Kong; Shesh N Rai; Roberto Bolli
Journal:  Stat Biopharm Res       Date:  2014-01-02       Impact factor: 1.452

2.  Practical considerations for optimal designs in clinical dose finding studies.

Authors:  Frank Bretz; Holger Dette; Jose C Pinheiro
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

3.  Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.

Authors:  Beibei Guo; Yisheng Li
Journal:  BMC Med Res Methodol       Date:  2014-07-29       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.